Recent decisions at the FDA threaten to turn its disagreements with the drugmaker UniQure into another political headache for ...

China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded ...

Vinay Prasad, a top official at the Food and Drug Administration who has been at the center of recurring public controversies, is exiting the agency for a second time. Prasad will leave the FDA at the ...

Servier said it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion.

For many religious objectors, including Amish, vaccination rejection is a situational interpretation of religious doctrine, ...

Stand Up For Science has become a formal organization and adopted a new strategy that's more confrontational with grassroots ...

The DOJ's fight against gender-affirming care, the impact of Trump's 'Don't take Tylenol,' and more health news ...

In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.

Meanwhile, Moderna is trying to reset its future around oncology.

Science Corp. raised $230 million as it awaits a decision from the FDA on PRIMA, its wireless retinal implant.

We recently worked on a National Academies of Sciences, Engineering, and Medicine (NASEM) report that lays out a clear blueprint for a national prevention infrastructure for mental and behavioral ...

Immediately after U.S. health officials linked Tylenol to autism, the drug's use in pregnant women visiting ERs dropped, new ...